Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B-Lymphocytes | 27 | 2023 | 79 | 5.760 |
Why?
|
| B-Lymphocyte Subsets | 14 | 2020 | 18 | 4.170 |
Why?
|
| T-Lymphocytes | 7 | 2023 | 140 | 3.430 |
Why?
|
| Antibody Formation | 10 | 2023 | 47 | 2.530 |
Why?
|
| Immunoglobulin M | 10 | 2020 | 19 | 2.270 |
Why?
|
| Mice, Inbred C57BL | 25 | 2023 | 792 | 2.240 |
Why?
|
| Mice | 46 | 2024 | 2571 | 2.000 |
Why?
|
| Pneumococcal Infections | 5 | 2021 | 30 | 1.670 |
Why?
|
| Pneumococcal Vaccines | 4 | 2021 | 28 | 1.650 |
Why?
|
| Lymphocyte Activation | 12 | 2021 | 94 | 1.510 |
Why?
|
| Peritoneal Neoplasms | 3 | 2020 | 256 | 1.460 |
Why?
|
| Animals | 52 | 2024 | 8196 | 1.420 |
Why?
|
| Cord Factors | 3 | 2020 | 3 | 1.410 |
Why?
|
| Lipid A | 3 | 2020 | 4 | 1.410 |
Why?
|
| Mice, Knockout | 18 | 2023 | 454 | 1.350 |
Why?
|
| Adjuvants, Immunologic | 9 | 2023 | 61 | 1.330 |
Why?
|
| Streptococcus pneumoniae | 5 | 2019 | 38 | 1.200 |
Why?
|
| Immunoglobulin G | 12 | 2022 | 129 | 1.190 |
Why?
|
| Receptors, Complement 3d | 9 | 2009 | 11 | 1.170 |
Why?
|
| Antigens, CD19 | 8 | 2018 | 9 | 1.140 |
Why?
|
| Immunity, Innate | 5 | 2018 | 82 | 1.140 |
Why?
|
| Antigens, T-Independent | 3 | 2020 | 3 | 1.060 |
Why?
|
| Signal Transduction | 15 | 2021 | 727 | 1.020 |
Why?
|
| Receptors, Complement 3b | 5 | 2009 | 7 | 0.990 |
Why?
|
| Immunologic Memory | 4 | 2021 | 33 | 0.970 |
Why?
|
| Antibodies, Bacterial | 5 | 2019 | 34 | 0.960 |
Why?
|
| Lectins, C-Type | 3 | 2020 | 14 | 0.920 |
Why?
|
| Toll-Like Receptors | 3 | 2020 | 30 | 0.910 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2020 | 13 | 0.780 |
Why?
|
| Polysaccharides | 2 | 2023 | 11 | 0.770 |
Why?
|
| Cell Differentiation | 7 | 2020 | 461 | 0.740 |
Why?
|
| Receptors, Antigen, B-Cell | 9 | 2023 | 12 | 0.730 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2020 | 46 | 0.730 |
Why?
|
| Peritoneal Cavity | 3 | 2018 | 5 | 0.640 |
Why?
|
| Antigens, Ly | 1 | 2020 | 7 | 0.630 |
Why?
|
| Interferon Type I | 1 | 2020 | 11 | 0.630 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 2016 | 3 | 0.620 |
Why?
|
| Polysaccharides, Bacterial | 5 | 2015 | 11 | 0.620 |
Why?
|
| Antigens | 3 | 2023 | 34 | 0.590 |
Why?
|
| Cells, Cultured | 13 | 2019 | 839 | 0.570 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 14 | 0.570 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 5 | 0.530 |
Why?
|
| Autoantibodies | 3 | 2014 | 50 | 0.520 |
Why?
|
| Immunity, Humoral | 6 | 2021 | 14 | 0.490 |
Why?
|
| Gene Expression Regulation | 5 | 2015 | 478 | 0.460 |
Why?
|
| Complement C4 | 1 | 2014 | 4 | 0.430 |
Why?
|
| Streptococcal Infections | 1 | 2014 | 23 | 0.430 |
Why?
|
| Primates | 1 | 2015 | 128 | 0.430 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2013 | 11 | 0.400 |
Why?
|
| Cell Proliferation | 5 | 2020 | 601 | 0.390 |
Why?
|
| Epitopes | 1 | 2013 | 26 | 0.390 |
Why?
|
| Antigens, CD20 | 6 | 2010 | 7 | 0.380 |
Why?
|
| Down-Regulation | 2 | 2019 | 131 | 0.370 |
Why?
|
| Homeostasis | 3 | 2021 | 130 | 0.370 |
Why?
|
| Growth Inhibitors | 2 | 2011 | 7 | 0.370 |
Why?
|
| Macrophages | 4 | 2020 | 207 | 0.350 |
Why?
|
| Neoplasms | 3 | 2016 | 763 | 0.350 |
Why?
|
| Antigens, Surface | 2 | 2015 | 24 | 0.330 |
Why?
|
| Autoimmunity | 3 | 2022 | 31 | 0.310 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 29 | 0.310 |
Why?
|
| Protein Binding | 5 | 2021 | 244 | 0.310 |
Why?
|
| Cattle | 6 | 2003 | 116 | 0.310 |
Why?
|
| Immunization | 4 | 2016 | 38 | 0.300 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 16 | 0.300 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 38 | 0.300 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 149 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 6 | 2010 | 245 | 0.290 |
Why?
|
| Lymphoid Tissue | 3 | 2023 | 11 | 0.280 |
Why?
|
| Female | 11 | 2024 | 19943 | 0.270 |
Why?
|
| Complement C3d | 2 | 2005 | 2 | 0.270 |
Why?
|
| Lymphocyte Depletion | 6 | 2010 | 18 | 0.260 |
Why?
|
| Leukemia, B-Cell | 1 | 2006 | 5 | 0.250 |
Why?
|
| Male | 9 | 2024 | 19437 | 0.240 |
Why?
|
| Receptor, trkA | 1 | 2024 | 2 | 0.220 |
Why?
|
| Phagocytes | 2 | 2020 | 5 | 0.210 |
Why?
|
| Humans | 16 | 2024 | 32271 | 0.210 |
Why?
|
| Mice, Transgenic | 4 | 2016 | 257 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 114 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 108 | 0.200 |
Why?
|
| Immunotherapy | 5 | 2008 | 91 | 0.200 |
Why?
|
| Bacterial Vaccines | 2 | 2019 | 8 | 0.200 |
Why?
|
| Cell Division | 3 | 2020 | 92 | 0.200 |
Why?
|
| Antibodies | 2 | 2008 | 56 | 0.190 |
Why?
|
| Trinitrobenzenes | 2 | 2013 | 2 | 0.190 |
Why?
|
| Ficoll | 2 | 2013 | 3 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1081 | 0.180 |
Why?
|
| Macaca fascicularis | 2 | 2015 | 542 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 3 | 2012 | 12 | 0.180 |
Why?
|
| Trypanosoma congolense | 1 | 2001 | 1 | 0.180 |
Why?
|
| Trypanosomiasis, African | 1 | 2001 | 6 | 0.180 |
Why?
|
| Sarcopenia | 1 | 2022 | 50 | 0.170 |
Why?
|
| Ligands | 5 | 2007 | 90 | 0.170 |
Why?
|
| Troponin T | 1 | 2022 | 92 | 0.160 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 5 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 422 | 0.160 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 2 | 0.160 |
Why?
|
| Immunoglobulin A | 2 | 2014 | 12 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2001 | 145 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 164 | 0.150 |
Why?
|
| Lymphoma | 1 | 2020 | 37 | 0.150 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 727 | 0.150 |
Why?
|
| Membrane Proteins | 1 | 2001 | 243 | 0.150 |
Why?
|
| Antigens, Nuclear | 1 | 2019 | 6 | 0.150 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2019 | 4 | 0.150 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 16 | 0.150 |
Why?
|
| Apoptosis | 2 | 2020 | 375 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 292 | 0.150 |
Why?
|
| Antibody-Producing Cells | 1 | 2019 | 4 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2013 | 61 | 0.150 |
Why?
|
| DNA Repair | 1 | 2019 | 55 | 0.140 |
Why?
|
| Vaccines, Conjugate | 1 | 2019 | 17 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2012 | 29 | 0.140 |
Why?
|
| Mice, Inbred A | 1 | 2018 | 5 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 257 | 0.140 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 3 | 0.130 |
Why?
|
| Interleukin-5 | 1 | 2017 | 7 | 0.130 |
Why?
|
| Complement System Proteins | 2 | 2009 | 7 | 0.130 |
Why?
|
| Syndecan-1 | 1 | 2017 | 20 | 0.130 |
Why?
|
| Vaccination | 1 | 2019 | 156 | 0.130 |
Why?
|
| Receptors, IgE | 2 | 2007 | 2 | 0.130 |
Why?
|
| Mucins | 1 | 2016 | 16 | 0.130 |
Why?
|
| Immunoglobulin E | 2 | 2007 | 36 | 0.120 |
Why?
|
| Receptors, IgG | 2 | 2008 | 7 | 0.120 |
Why?
|
| Spleen | 3 | 2013 | 84 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2015 | 476 | 0.120 |
Why?
|
| Cell Survival | 3 | 2006 | 286 | 0.120 |
Why?
|
| Carbohydrates | 1 | 2016 | 10 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2017 | 183 | 0.120 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 3 | 2005 | 5 | 0.120 |
Why?
|
| Lectins | 3 | 2005 | 11 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 27 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 3 | 2005 | 38 | 0.120 |
Why?
|
| Cytokines | 3 | 2008 | 237 | 0.120 |
Why?
|
| Antigens, CD | 3 | 2005 | 97 | 0.120 |
Why?
|
| src-Family Kinases | 3 | 2005 | 15 | 0.110 |
Why?
|
| Phenotype | 4 | 2015 | 622 | 0.110 |
Why?
|
| Species Specificity | 1 | 2015 | 98 | 0.110 |
Why?
|
| Cross Reactions | 1 | 2014 | 5 | 0.110 |
Why?
|
| Lipopeptides | 1 | 2014 | 7 | 0.110 |
Why?
|
| Phosphatidylcholines | 1 | 2014 | 29 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2014 | 15 | 0.110 |
Why?
|
| Calcium | 3 | 2006 | 339 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 764 | 0.100 |
Why?
|
| DNA | 1 | 2014 | 223 | 0.100 |
Why?
|
| Mutation | 2 | 2024 | 497 | 0.090 |
Why?
|
| Diet | 1 | 2015 | 383 | 0.090 |
Why?
|
| Haptens | 1 | 2011 | 2 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 163 | 0.090 |
Why?
|
| Splenectomy | 1 | 2011 | 22 | 0.090 |
Why?
|
| Cysteine | 1 | 2012 | 145 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 821 | 0.090 |
Why?
|
| Kidney | 1 | 2014 | 521 | 0.080 |
Why?
|
| Immunophenotyping | 4 | 2008 | 47 | 0.080 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2010 | 1 | 0.080 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 4 | 0.080 |
Why?
|
| Mice, Inbred NZB | 1 | 2010 | 4 | 0.080 |
Why?
|
| Terpenes | 1 | 2010 | 6 | 0.080 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 21 | 0.080 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 25 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1178 | 0.080 |
Why?
|
| Receptors, Fc | 2 | 2006 | 6 | 0.080 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 15 | 0.080 |
Why?
|
| Inflammation | 2 | 2015 | 507 | 0.080 |
Why?
|
| CD40 Ligand | 3 | 2011 | 12 | 0.070 |
Why?
|
| Time Factors | 2 | 2011 | 2203 | 0.070 |
Why?
|
| Models, Biological | 3 | 2007 | 408 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2008 | 31 | 0.070 |
Why?
|
| Plasma Cells | 1 | 2008 | 12 | 0.070 |
Why?
|
| Prions | 1 | 2007 | 2 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 892 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1111 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2007 | 66 | 0.060 |
Why?
|
| Nippostrongylus | 1 | 2007 | 1 | 0.060 |
Why?
|
| Strongylida Infections | 1 | 2007 | 2 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 33 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2006 | 101 | 0.060 |
Why?
|
| Immunity, Cellular | 2 | 2002 | 21 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2003 | 499 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2005 | 11 | 0.060 |
Why?
|
| Scleroderma, Systemic | 1 | 2005 | 8 | 0.060 |
Why?
|
| Immune System | 1 | 2005 | 7 | 0.060 |
Why?
|
| Indazoles | 1 | 2024 | 4 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2004 | 2 | 0.050 |
Why?
|
| Benzamides | 1 | 2024 | 60 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2005 | 66 | 0.050 |
Why?
|
| HIV Antibodies | 1 | 2004 | 2 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2004 | 4 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2004 | 3 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2004 | 4 | 0.050 |
Why?
|
| Streptavidin | 1 | 2004 | 2 | 0.050 |
Why?
|
| Bacteria | 1 | 2005 | 54 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2004 | 12 | 0.050 |
Why?
|
| Cullin Proteins | 1 | 2004 | 6 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 99 | 0.050 |
Why?
|
| HIV-1 | 1 | 2004 | 46 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 38 | 0.050 |
Why?
|
| Cell Line | 2 | 2004 | 454 | 0.050 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2004 | 49 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 52 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2003 | 7 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 74 | 0.050 |
Why?
|
| Parasitic Diseases | 1 | 2002 | 3 | 0.050 |
Why?
|
| Receptors, Mitogen | 1 | 2002 | 2 | 0.050 |
Why?
|
| Immunity | 1 | 2002 | 19 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2002 | 14 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2002 | 13 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 45 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2003 | 61 | 0.050 |
Why?
|
| Proteins | 1 | 2003 | 149 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2001 | 73 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2001 | 4 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 20 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2001 | 55 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 120 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2022 | 208 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2000 | 4 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 111 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2012 | 250 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 170 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 591 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 520 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 246 | 0.030 |
Why?
|
| Autoimmune Diseases | 2 | 2008 | 46 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2007 | 109 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 138 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 24 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 43 | 0.030 |
Why?
|
| Calcium Signaling | 2 | 2005 | 49 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 563 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 8 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2012 | 9 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2012 | 10 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 26 | 0.020 |
Why?
|
| Cyclohexanones | 1 | 2012 | 20 | 0.020 |
Why?
|
| Actins | 1 | 2012 | 54 | 0.020 |
Why?
|
| Biological Transport | 1 | 2012 | 75 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2015 | 320 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 51 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 184 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 299 | 0.020 |
Why?
|
| Aged | 1 | 2022 | 10249 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2008 | 1 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 49 | 0.020 |
Why?
|
| Integrin alpha4beta1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Prion Diseases | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 55 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 114 | 0.020 |
Why?
|
| Antigens, Helminth | 1 | 2007 | 1 | 0.020 |
Why?
|
| Alum Compounds | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 36 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2007 | 22 | 0.020 |
Why?
|
| Silver | 1 | 2007 | 8 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2006 | 10 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 196 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 39 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2005 | 17 | 0.010 |
Why?
|
| Complement C3 | 1 | 2005 | 11 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2005 | 8 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 250 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2004 | 31 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 55 | 0.010 |
Why?
|
| Hybridomas | 1 | 2004 | 3 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 167 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 95 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 74 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 7 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 31 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 33 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2003 | 8 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 35 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 83 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 80 | 0.010 |
Why?
|
| Leukocytes | 1 | 2003 | 60 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 63 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 9 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 252 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 290 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 74 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 359 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 264 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2002 | 9 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2002 | 17 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 140 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2003 | 78 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 3408 | 0.010 |
Why?
|